Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.72 | 0.00 | 1.64 |
| FCF Yield | -0.95% | -1.00% | -0.88% | -0.98% |
| EV / EBITDA | -98.17 | -93.41 | -275.89 | -245.47 |
| Quality | ||||
| ROIC | -5.94% | -5.94% | -4.57% | -4.57% |
| Gross Margin | 96.17% | 96.17% | 97.80% | 97.80% |
| Cash Conversion Ratio | 0.94 | 0.94 | 1.17 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 51.50% | 46.83% | 51.23% | 25.52% |
| Free Cash Flow Growth | 0.00% | 0.48% | 0.00% | 0.53% |
| Safety | ||||
| Net Debt / EBITDA | 10.54 | 10.54 | 35.73 | 35.66 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.52 | 0.52 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,883.91 | -2,883.91 | -5,023.34 | -5,023.34 |